Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Catalyst Pharmaceutical Partners Inc

+ Add to Watchlist

CN2:GR

3.303 EUR 0.039 1.17%

As of 13:03:20 ET on 02/27/2015.

Snapshot for Catalyst Pharmaceutical Partners Inc (CN2)

Open: 3.318 Day's Range: 3.303 - 3.389 Volume: 143
Previous Close: 3.342 52wk Range: 1.236 - 3.389 1-Yr Rtn: +98.02%

Stock Chart for CN2

No chart data available.
  • CN2:GR 3.389
  • 1D
  • 1M
  • 1Y
3.342
Interactive CN2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CN2

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.2430
Est. PEG Ratio -
Market Cap (M EUR) 261.33
Shares Outstanding (M) 79.12
30 Day Average Volume 370
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/19/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CN2

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CN2

Catalyst Pharmaceutical Partners, Inc. is a pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company develops drugs for addictions such as methamphetamine, nicotine, prescription pain medications, alcohol, and marijuana, as well as treatments for related addictive disorders, such as obesity and gambling.

Patrick J McEnanyChairman/President/CEO/Co-FounderSteven R MillerChief Operating Officer
Charles W GorodetzkyChief Medical OfficerDavid D MuthExec VP/Chief Commercial Officer
More Company Profile & Key Executives for CN2

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil